Investigation of the efficacy of 99 mTc-DTPA scintigraphic GFR measurement with Gates method in the detection of cisplatin-induced nephrotoxicity in comparison with plasma urea and creatinine measurement.
In this study, we investigated the efficacy of 99mTc-DTPA scintigraphic analysis of GFR with the Gates method in comparison with the measurement of plasma urea and creatinine, in the detection of nephrotoxicity occurred in patients treated with cisplatin.Twenty-six male patients with a mean age of 26.73±6.39 years (age range 15-42) who had seminomatous and nonseminomatous testicular carcinoma were included in our study. The patients received cisplatin with a dose of 20 mg/m2 per day for five consecutive days repeated every 21 days. Before starting chemotherapy, immediately after the end of four cycles of chemotherapy and 7 months after the beginning of chemotherapy, plasma urea and creatinine levels were measured and simultaneously scintigraphic GFR estimation using 99 mTc-DTPA with the Gates method was performed. In the measurements done immediately after the chemotherapy, in 18 of the 26 patients GFR levels decreased, in 4 of the 8 remaining patients GFR did not change, and in 4 patients there was an increase in the GFR levels. The changes in the averages of the plasma urea and creatinine levels between measurements done before and after the chemotherapy were not statistically significant. The decrease in the average of the GFR values immediately after chemotherapy, in comparison to the average of GFR values measured before chemotherapy, was found to be statistically significant with paired sample t test analysis (P<0.009 with 95% CI). We concluded that scintigraphic GFR measurement using the Gates method with 99mTc-DTPA is a suitable method in the diagnosis of nephrotoxicity occuring due to cisplatine.
Özülker
Filiz
F
Department of Nuclear Medicine, Okmeydani Training and Research Hospital, İstanbul, Turkey.
Özülker
Tamer
T
Uzun
Aysun Küçüköz
AK
Özpaçacı
Tevfik
T
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005919:Glomerular Filtration Rate; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000139:chemically induced / Q000000981:diagnostic imaging*; D008297:Male; D011877:Radionuclide Imaging / Q000379:methods; D019275:Radiopharmaceuticals; D016284:Technetium Tc 99m Pentetate; D013736:Testicular Neoplasms / Q000188:drug therapy; D014508:Urea / Q000097:blood; D055815:Young Adult
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D014508:Urea; D003404:Creatinine; D002945:Cisplatin; D016284:Technetium Tc 99m Pentetate
Ann Oncol. 1999 Dec;10(12):1475-83
10643539
Cancer Treat Rev. 1998 Aug;24(4):265-81
9805507
Br J Cancer. 1998 May;77(10):1677-82
9635848
Clin Pharmacol Ther. 1978 Apr;23(4):461-6
415836
J Urol. 1976 Sep;116(3):282-5
785027
Clin Pharmacol Ther. 1988 Aug;44(2):164-72
2840230
Am J Nephrol. 1994;14(2):81-4
8080010
Am J Kidney Dis. 1986 Sep;8(3):164-9
3752072
Toxicol Lett. 1989 Aug;48(2):193-9
2772925
Toxicol Appl Pharmacol. 1988 Feb;92(2):157-69
2963406
Nephrologie. 1993;14(5):227-9
8159252
Biochem Biophys Res Commun. 1989 Mar 31;159(3):1121-7
2930553
Clin Sci (Lond). 1988 Aug;75(2):203-7
3409636
AJR Am J Roentgenol. 1982 Mar;138(3):565-70
7039273
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1475-83
159127